Compounds for enzyme inhibition

Details Compounds for enzyme inhibition Compounds for enzyme inhibition

2007-06-19

2007-06-19

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S254100, C514S326000, C514S407000, C514S422000, C514S475000, C544S147000, C544S374000, C546S207000, C548S370100, C548S517000, C549S548000

Reexamination Certificate

active

11106879

ABSTRACT:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

REFERENCES:
patent: 5071957 (1991-12-01), Konishi et al.
patent: 5340736 (1994-08-01), Goldberg
patent: 6099851 (2000-08-01), Weisman et al.
patent: 6204257 (2001-03-01), Stella et al.
patent: 6410512 (2002-06-01), Mundy et al.
patent: 6462019 (2002-10-01), Mundy et al.
patent: 6492333 (2002-12-01), Mundy
patent: 6656904 (2003-12-01), Mundy et al.
patent: 6831099 (2004-12-01), Crews et al.
patent: 6838252 (2005-01-01), Mundy et al.
patent: 6838436 (2005-01-01), Mundy et al.
patent: 6884769 (2005-04-01), Mundy et al.
patent: 6902721 (2005-06-01), Mundy et al.
patent: 2004/0266664 (2004-12-01), Crews et al.
patent: 2005/0256324 (2005-11-01), Laidig et al.
patent: 2006/0030533 (2006-02-01), Smyth et al.
patent: 0 411 660 (1991-02-01), None
patent: WO-00/02548 (2000-01-01), None
patent: WO-00/61167 (2000-10-01), None
patent: WO-01/28579 (2001-04-01), None
patent: WO-03/059898 (2003-07-01), None
patent: WO-2005/111008 (2005-11-01), None
Dobler, M. R., “Total synthesis of (+)-epopromycin B and its analogues-studies on the inhibition of cellulose biosynthesis,” Tetrahedron Letters, 42(2):215-218 (2001).
Oishi et al., “Diastereoselective synthesis of new psi '(E)-CH=CMel- and psi '(Z)-CH=CMel-type alkene dipeptide isosteres by organocopper reagents and application to conformationally restricted cyclic RGD peptidomimetics,”J. Org. Chem., 67:6162-6173 (2002).
Myung et al., “Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors,”Molecular Cell, vol. 7, No. 2, pp. 411-420, 2001.
Myung et al., “The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors,”Medicinal Research Reviews, vol. 21, No. 4, pp. 245-273, 2001.
Adams et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents”,Cancer Research, vol. 59, pp. 2615-2622, 1999.
Benedetti et al., “Versatile and Stereoselective Synthesis of Diamino Diol Dipeptide Isosteres, Core Units of Pseudopeptide HIV Protease Inhibitors”,J. Org. Chem., vol. 62, pp. 9348-9353, 1997.
Bougauchi et al., “Catalytic Asymmetric Epoxidation of α, β-Unsaturated Ketones Promoted by Lanthanoid Complexes”,J. Am. Chem. Soc., vol. 119, pp. 2329-2330, 1997.
Brown et al., “Selective Reductions. 37. Asymmetric Reduction of Prochiral Ketones with β-(3-Pinanyl)-9-borabicyclo[3.3.1]nonane”,J. Org. Chem., vol. 50, pp. 1384-1394, 1985.
Ciechanover, “The Ubiquitin-Proteasome Proteolytic Pathway”,Cell, vol. 79, pp. 13-21, 1994.
Cohen, “AIDS Mood Upbeat-For a Change”,Science, vol. 267, pp. 959-960, 1995.
Corey et al., “A General, Catalytic, and Enantioselective Synthesis of α-Amino Acids”,J. Am. Chem. Soc., vol. 114, pp. 1906-1908, 1992.
Corey et al., “Highly Enantioselective Borane Reduction of Ketones Catalyzed by Chiral Oxazaborolidines. Mechanism and Synthetic Implications”,J. Am. Chem. Soc., vol. 109, pp. 5551-5553, 1987.
Datta et al., “A Stereoselective Route to Hydroxyethylamine Dipeptide Isosteres”,J. Am. Chem. Soc., vol. 65, pp. 7609-7611, 2000.
Dess et al., “A Useful 12-I-5 Triacetoxyperiodinane (the Dess-Martin Periodinane) for the Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-I-5 Species”,J. Am. Chem. Soc., vol. 113, pp. 7277-7287, 1991.
Dess et al., “Readily Accessible 12-I-5 Oxidant for the Conversion of Primary and Secondary Alcohols to Aldehydes and Ketones”,J. Org. Chem., vol. 48, pp. 4155-4156, 1983.
Elofsson et al., “Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′,β′-epoxyketones”,Chemistry&Biology, vol. 6, pp. 811-822, 1999.
Garrett et al., “Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro”,J Clinical Investigation, vol. 111, pp. 1771-1782, 2003.
Hanson et al., “Synthesis of New Dipeptide Analogues Containing Novel Ketovinyl and Hydroxyethylidene Isosteres via Grignard Addition to Chiral α-Amino Aldehydes”,J. Org. Chem., vol. 50, pp. 5399-5401, 1985.
Harding et al., “Novel Dipeptide Aldehydes Are Proteasome Inhibitors and Block the MHC-1 Antigen-Processing Pathway”,J. Immunology, vol. 155, pp. 1767-1775, 1995.
Hardy, “The secret life of the hair follicle”,Trends in Genetics, vol. 8, pp. 55-61, 1992.
Hoffmen et al., “Highly Stereoselective Syntheses ofsyn-andanti-1,2-Amino Alcohols”,J. Org. Chem., vol. 67, pp. 1045-1056, 2002.
Iqbal et al., “Potent α-ketocarbonyl and boronic ester derived inhibitors of proteasome”,Bioorganic&Medicinal Chemistry Letters, vol. 6, pp. 287-290, 1996.
Jacobsen et al., “Asymmetric Dihydroxylation via Ligand-Accelerated Catalysis”,J. Am. Chem. Soc., vol. 110, pp. 1968-1970, 1988.
Jones et al., “Total Synthesis of the Immunosuppressant (-)-FK-506”,J. Am. Chem. Soc., vol. 111, pp. 1157-1159, 1989.
Kim et al., “Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency”,Bioorganic&Medicinal Chemistry Letters, vol. 9, pp. 3335-3340, 1999.
Kumatori et al., “Abnormally high expression of proteasomes in human leukemic cells”,Proc. Natl. Acad. Sci. USA, vol. 87, pp. 7071-7075, 1990.
Liang et al., “Synthesis of Cryptophycin 52 Using the Sharpless Asymmetric Dihydroxylation: Diol to Epoxide Transformation Optimized for a Base-Sensitive Substrate”,J. Am. Chem. Soc., vol. 65, pp. 3143-3147, 2000.
Marx et al., “Reactivity-Selectivity in the Swern Oxidation of Alcohols Using Dimethyl Sulfoxide-Oxalyl Chloride”,J. Org. Chem., vol. 49, pp. 788-793, 1984.
Meng et al., “Eponemycin Exerts Its Antitumor Effect through the Inhibition of Proteasome Function”,Cancer Research, vol. 59, pp. 2798-2801, 1999.
Meng et al., “Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflamatory activity”,Proc. Natl. Acad. Sci. USA, vol. 96, pp. 10403-10408, 1999.
Nemoto et al., “Catalytic Asymmetric Epoxidation of Enones Using La-BINOL-Triphenylarsine Oxide Complex: Structural Determination of the Asymmetric Catalyst”,J. Am. Chem. Soc., vol. 123, pp. 2725-2732, 2001.
Palombella et al., “The Ubiquitin-Proteasome Pathway Is Required for Processing the NF-kB1 Precursor Protein and the Activation of NF-kB”,Cell, vol. 78, pp. 773-785, 1994.
Paugam et al., “Characterization and role of protozoan parasite proteasomes”,Trends Parasitol., vol. 19, pp. 55-59, 2003.
Qureshi et al., “The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events”,J. Immunology, vol. 171, pp. 1515-1525, 2003.
Shao et al., “A New Asymmetric Synthesis of α-Methylcysteines via Chiral Aziridines”,J. Org. Chem., vol. 60, pp. 790-791, 1995.
Sharpless et al., “High Stereo- and Regioselectivities in the Transition Metal Catalyzed Epoxidations of Olefinic Alcohols by tert-Butyl Hydroperoxide”,J. Am. Chem. Soc., vol. 95, pp. 6136-6137, 1973.
Sin et al., “Total synthesis of the

Affiliated with

Also associated with

Rating

Compounds for enzyme inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for enzyme inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for enzyme inhibition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3807027